
Chemical and Pharmaceutical Bulletin p. 1964 - 1972 (2000)
Update date:2022-07-29
Topics:
Okada, Yoshio
Tsuda, Yuko
Tada, Mayako
Wanaka, Keiko
Okamoto, Utako
Hijikata-Okunomiya, Akiko
Okamoto, Shosuke
Based on structure-activity relationship studies, we designed and synthesized plasmin (PL) and plasma kallikrein (PK) inhibitors. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-PIC)-octylamide inhibited PL, PK, urokinase (UK) and thrombin (TH) with IC50 values of 0.53, 30, 5.3 and >400 μM, respectively. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-2-Pyrim)-4-carboxyanilide inhibited PL, PK, UK and TH with IC50 values of 36, 0.56, 440 and >1000 μM, respectively.
View MoreShantou Baokang Pharmaceutical Co., Ltd.
Contact:+86-754-88873487
Address:5/F B Block Huangshan Bldg Huangshan Rd Shantou
Tianjin Bright Future Technology Co., Ltd
Contact:0086-22-58016666
Address:NO.136 DongTeng Lake Street Tianjin Economic and Technology Development Area,Tainjin,China
CHANGZHOU HANGYU PHARMACEUTICAL TECHNOLOGY CO., LTD
website:http://www.czyys.com
Contact:0086-519-88802789
Address:No.300,Yanling Middle Road, Changzhou, Jiangsu, China
SHANDONG QINGYUNCHANGXIN CHEMICAL SCIENCE-TECH CO.,LTD
Contact:86-21-60560171
Address:1689Donghuan Rade,Qingyun County, Dezhou City, Shandong,China
Henan zhongda Biological Engineering Co., Ltd
Contact:86-28-18109029985
Address:shenzhou road,xuedian industrial estate,zhengzhou city,henan province CHN
Doi:10.1016/j.jorganchem.2014.06.018
(2014)Doi:10.1039/c9cc06638a
(2019)Doi:10.1016/j.bmcl.2007.04.089
(2007)Doi:10.1021/acs.joc.9b03155
(2020)Doi:10.1039/b007626k
(2000)Doi:10.1016/S0040-4020(01)98216-X
(1971)